Combination immune checkpoint blockade in advanced untreated gastroesophageal adenocarcinoma: Seeking biomarkers for...

Area of Science:

• Oncology
• Gastrointestinal Oncology
• Immunotherapy

Background:

• Advanced gastroesophageal adenocarcinoma presents a significant treatment challenge.
• Identifying effective first-line treatment strategies is crucial for improving patient outcomes.

Purpose of the Study:

• To evaluate the efficacy of nivolumab combined with chemotherapy versus chemotherapy alone in treatment-naive patients with advanced gastroesophageal adenocarcinoma.
• To assess the efficacy of nivolumab plus ipilimumab compared to chemotherapy in the same patient population.

Main Methods:

• The study involved a randomized controlled trial design, the CheckMate 649 trial.
• Patients received either chemotherapy plus nivolumab or chemotherapy alone.
• An additional arm compared nivolumab plus ipilimumab to chemotherapy.

Main Results:

• Chemotherapy plus nivolumab demonstrated superior efficacy, establishing it as a new standard of care.
• Patients with high PD-L1 expression and microsatellite unstable tumors showed the best response to chemotherapy plus nivolumab.
• Nivolumab plus ipilimumab showed early progression and no overall survival benefit compared to chemotherapy.

Conclusions:

• Chemotherapy plus nivolumab is a recommended first-line treatment for advanced gastroesophageal adenocarcinoma, particularly in biomarker-selected subgroups.
• Nivolumab plus ipilimumab is not recommended as a first-line treatment for this indication based on these findings.